Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Recommendation of "Buy" by Analysts

Key Points

• Lucid Diagnostics Inc. has received a consensus recommendation of "Buy" from five research firms, with an average twelve-month price target of $3.65.
• The stock's recent performance shows a market cap of $137.48 million and has traded between a one-year low of $0.75 and a high of $1.80.
• Recent insider trading includes a purchase of 100,000 shares by Director Dennis Matheis, increasing his ownership by 17.69%.

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) have received a consensus recommendation of "Buy" from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $3.65.

LUCD has been the topic of several analyst reports. Ascendiant Capital Markets increased their price target on Lucid Diagnostics from $7.50 to $7.75 and gave the stock a "buy" rating in a research report on Friday, June 6th. BTIG Research increased their price target on Lucid Diagnostics from $2.00 to $2.50 and gave the stock a "buy" rating in a research report on Friday, September 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $3.00 price target on shares of Lucid Diagnostics in a research report on Wednesday, August 13th. Finally, Wall Street Zen raised Lucid Diagnostics from a "sell" rating to a "hold" rating in a research report on Sunday.

Lucid Diagnostics Price Performance

NASDAQ LUCD opened at $1.03 on Tuesday. The stock's fifty day moving average price is $1.09 and its 200 day moving average price is $1.23. Lucid Diagnostics has a 1 year low of $0.75 and a 1 year high of $1.80. The company has a market cap of $137.48 million, a price-to-earnings ratio of -0.87 and a beta of 1.24.

Insiders Place Their Bets

In other Lucid Diagnostics news, Director Dennis Matheis bought 100,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were purchased at an average cost of $1.02 per share, for a total transaction of $102,000.00. Following the transaction, the director directly owned 665,443 shares of the company's stock, valued at approximately $678,751.86. The trade was a 17.69% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 6.80% of the company's stock.

Institutional Investors Weigh In On Lucid Diagnostics

A number of institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Lucid Diagnostics during the 2nd quarter valued at about $43,000. Invesco Ltd. purchased a new position in Lucid Diagnostics in the 2nd quarter valued at about $41,000. New York State Common Retirement Fund purchased a new position in Lucid Diagnostics in the 2nd quarter worth approximately $97,000. Quadrature Capital Ltd purchased a new stake in shares of Lucid Diagnostics in the second quarter valued at approximately $29,000. Finally, JPMorgan Chase & Co. grew its position in shares of Lucid Diagnostics by 71,026.1% in the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company's stock valued at $38,000 after purchasing an additional 32,672 shares in the last quarter. 74.01% of the stock is currently owned by institutional investors and hedge funds.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.